Targeting NFAT2 for Reversing the P-gp-Mediated Multidrug Resistance to Paclitaxel by Manidipine
In sum, all these results position MA as a novel NFAT2 inhibitor to overcome P-gp-mediated MDR via modulating calcium signaling, which points to further investigation for its clinical applications.
Authors
- Qian Li (ORCID: https://orcid.org/0009-0000-4732-6233)
- Jian Zhou (ORCID: https://orcid.org/0000-0002-0749-1354)
- Yukang Lin (ORCID: https://orcid.org/0000-0001-8586-8682)
- Hua Zhou (ORCID: https://orcid.org/0000-0002-7025-3690)
- Nan Wang (ORCID: https://orcid.org/0000-0002-9589-1621)
- Ying Xie (ORCID: https://orcid.org/0000-0003-3223-1797)
- Hai Lan (ORCID: https://orcid.org/0000-0002-9668-7593)
- Rui-Ming Liu
- Jia-Qin Hu
Institutions
- Macau University of Science and Technology (MO)
- Guangzhou University of Chinese Medicine (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3390/cancers17203289
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00